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Aberrant posttranslational modifications of proteins can impair synaptic plasticity and may render neurons
vulnerable to degeneration during aging. In this issue of Neuron, Min et al. show that acetylation of the amino
acid lysine in the microtubule-associated protein tau prevents its ubiquitin-mediated degradation, resulting
in ‘‘tau tangles’’ similar to those of dementias. Other recent studies suggest that lysine hyperacetylation
contributes to the accumulation of amyloid b-peptide in Alzheimer’s disease and to impaired cognitive
function resulting from a trophic factor deficit.Learning and memory and associated
forms of information processing involve
complex neuronal networks distributed
throughout the cerebral cortex, hippo-
campus, and associated structures.
Research during the past century has
elucidated fundamental requirements for
normal cognitive function which include
the following: a sufficient number of
neurons with axons and dendritic arbors
capable of both maintenance and modifi-
cation of their structure; synapses that
transmit electrochemical signals between
neurons; and activity-dependent neuro-
trophic factor-mediated modification of
neuroarchitecture and synaptic strength.
The biochemical processes that control
the structure and function of neuronal
networks involve tightly controlled
production, placement, and removal of
proteins, as well as rapid modulation of
protein functions (enzymatic activity,
binding to other proteins, conformational
change, etc.). In many cases, reversible
posttranslational modification of one or
more specific amino acids is the key to
control of a protein’s function. Thus,
phosphorylation of serine, threonine,
and/or tyrosine residues has been shown
to regulate numerous proteins involved in
learning and memory, including neuro-
transmitter receptors and associated
proteins, ion channels, and synaptic
vesicle-associated proteins (Wayman
et al., 2008). In addition, a major mecha-
nism for the removal of spent proteins
involves ubiquitination on lysine, a diet-
derived amino acid, which targets the
protein for degradation in the proteasome
(Yang and Seto, 2008). Scientists at the
Gladstone Institute and the University of
California at San Francisco now report900 Neuron 67, September 23, 2010 ª2010 Ethat excessive acetylation of specific
lysine residues in the tau protein prevents
ubiquitination of those same lysine resi-
dues, thereby reducing the degradation
of tau (Min et al., 2010). As a result, tau
accumulates inside neurons in a manner
similar to that seen in Alzheimer’s disease
(AD), frontotemporal dementia (FTD), and
other ‘‘tauopathies.’’
The tau in neurons affected in AD is
hyperphosphorylated on amino acids
threonine 231 and threonine 181 (p-tau),
which may result from increased activity
of a protein kinase or decreased activity
of a protein phosphatase (Goedert et al.,
2006). However, the abnormal aggrega-
tion of tau in tauopathies is not readily
explained by altered phosphorylation
because p-tau is also present in robustly
healthy neurons during brain develop-
ment. Tau is believed to be ubiquitinated
and degraded by the proteasome (Petru-
celli et al., 2004) and impaired protea-
some-mediated clearance of proteins is
implicated in the pathogenesis of neuro-
degenerative disorders: a-synuclein in
Parkinson’s disease, huntingtin in Hun-
tington’s disease, and superoxide dismu-
tase 1 in amyotrophic lateral sclerosis.
Besides being ubiquitinated, lysine resi-
dues can be acetylated, a process regu-
lated by lysine acetyltransferases and
lysine deacetylases (Yang and Seto,
2008). Min et al. (2010) asked whether
acetylation of tau might affect its clear-
ance by the proteasome. They developed
antibodies that only recognized tau when
it was acetylated on specific lysines (163,
174, and 180); these antibodies allowed
them to establish that tau acetylation is
abnormally high in the brains of AD
patients, even at an early stage of thelsevier Inc.disease. Further investigation in cultured
cells revealed that lysine acetyltransfer-
ase p300 acetylated, whereas the lysine
deacetylase SIRT1 deacetylated, tau at
the designated sites. Next, it was shown
that genetic deletion of SIRT1 increases
tau acetylation in cultured neurons and
in the brains of adult mice and that this
resulted in the accumulation of p-tau
(Figure 1). Additional evidence suggested
that acetylation of tau inhibited its protea-
somal degradation, apparently by pre-
venting ubiquitination of the lysines.
Finally, a small molecule inhibitor of
p300 prevented the accumulation of
p-tau in neurons, including the excessive
p-tau resulting from a mutation that
causes FTD (Min et al., 2010).
Intraneuronal accumulation of p-tau
aggregates, including paired-helical fila-
ments, is strongly correlated with cogni-
tive performance in AD, FTD, and even
normal aging (Stomrud et al., 2010), and
studies of human tau transgenic mice
have demonstrated that accumulation of
p-tau is sufficient to cause cognitive
impairment (Polydoro et al., 2009).
A next step toward establishing the
importance of tau acetylation state in
dementias will be to determine if and
how manipulations of tau acetylation
affect synaptic plasticity and cognitive
function. A recent study of mice lacking
or overexpressing SIRT1 in their neurons
provided evidence that SIRT1 is essential
for hippocampal synaptic plasticity and
learning and memory (Micha´n et al.,
2010). However, because tau is only one
of many different substrates for lysine
acetyltransferases and deacetylases, in-
hibiting acetyltransferases or increasing
the activity of SIRT1 alone cannot
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Figure 1. Hyperacetylation of Multiple Proteins Creates Havoc in Systems Regulating Neuronal Plasticity, Resulting in Pathological
Accumulations of Tau and Ab and Impaired Neurotrophic Signaling
(A) In neurons in neurologically normal individuals, tau is only lightly acetylated (yellow ovals represent acetyl groups) and interacts with microtubules in a dynamic
manner to control their polymerization state, thereby enabling processes such as axonal transport and neurite outgrowth. In tauopathies, such as Alzheimers’
disease (AD) and frontotemporal dementia (FTD), tau is excessively phosphorylated (gray circles) and acetylated (yellow ovals). The hyperphosphorylation of
tau reduces its binding to microtubules, and hyperacetylation prevents ubiquitin-mediated proteolysis of p-tau, thereby promoting self-aggregation of tau. As
a result, microtubules depolymerize and tau filaments accumulate inside neurons. Hyperacetylation of tau may result from decreased SIRT activity or increased
activity of the lysine acetyltransferase p300.
(B) The b-amyloid precursor protein (APP), the source of amyloid b-peptide (Ab, red), is cleaved in themiddle of the Ab sequence by an enzyme called a-secretase
(a-s), resulting in the release of a secreted form of APP (sAPPa) from the cell surface. sAPPamodulates neuronal excitability and synaptic plasticity and promotes
neuronal survival as well. The expression of a-s is induced by a transcription factor called retinoic acid receptor-b (RARb), which is activated when it is deacety-
lated by the lysine deacetylase SIRT1. In AD, RARb is hyperacetylated, resulting in reduced expression of a-s and alternative cleavage of APP by b-secretase (b-s)
and g-secretase (g-s). In this way, excessive amounts of Ab are produced, which then self-aggregates on the surface of neurons, resulting in their dysfunction and
degeneration.
(C) In healthy individuals, activity in neuronal circuits results in the activation of the transcription factor CREB (cyclic AMP response element-binding protein),
which induces the expression of brain-derived neurotrophic factor (BDNF). BDNF, in turn, activates signaling pathways, in the same neuron and synaptically con-
nected neurons, that promote neuronal survival, synaptic plasticity and cognitive processing of information. The latter activity-dependent pathway is enabled by
the transcriptional repressor YY1, which suppresses the expression of a micro RNA (miR134) that targets the CREB mRNA. The activity of YY1 is enhanced by
SIRT1-mediated deacetylation. In neurodegenerative dementing disorders, YY1 may be hyperacetylated, resulting in derepression of miR134 expression,
suppression of CREB translation, and reduction in BDNF expression.
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Previewsestablishwhich protein substrate(s) is crit-
ical for the observed phenotype. Sub-
stituting a different amino acid for
a specific lysine residue in tau and other
relevant proteins of interest is one
approach that may help establish the rela-
tive contribution of tau acetylation to the
pathogenesis of AD and other tauopa-
thies.
Might protein acetylation also be
involved in Ab accumulation in the brain,
the second major feature of AD? An
answer to this question is provided by
findings from a recent study showing
that overexpression of SIRT1 in the brains
of ‘‘AD mice’’ (mice that express AD-causing mutant forms of human APP
and presenilin-1) reduces Ab accumula-
tion and, conversely, knocking out SIRT1
exacerbates Ab accumulation (Donmez
et al., 2010). Ab is produced by sequential
proteolytic cleavages of APP by b- and g-
secretases, with presenilin-1 being the
enzymatic component of g-secretase;
another enzyme, a-secretase (ADAM10),
cleaves APP in the middle of the Ab
sequence, thereby preventing Ab produc-
tion (Figure 1). It was previously demon-
strated that overexpression of human
SIRT1 in mice results in increased a-sec-
retase activity levels (Qin et al., 2006).
Donmez et al. (2010) found that SIRT1Neuron 67, Seinduces the expression of ADAM10 by
a mechanism involving deacetylation
and activation of the retinoic acid receptor
b (RARb) (Figure 1). Reduction in a-secre-
tase levels as a result of hyperacetylation
of RARb may, therefore, contribute to the
pathological accumulation of Ab and its
destructive effects on neurons in AD.
The activity-dependent production of
brain-derived neurotrophic factor (BDNF)
is essential for synaptic plasticity and
cognitive processes and also protects
neurons against potentially damaging
free radicals and excitotoxic and meta-
bolic stress (Mattson et al., 2004).
An intriguing role for protein acetylationptember 23, 2010 ª2010 Elsevier Inc. 901
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Previewsin the regulation of synaptic plasticity and
memory via modulation of BDNF expres-
sion was recently described (Gao et al.,
2010). Neural cell-specific SIRT1 defi-
ciency results in impaired learning and
memory in mice as a result of reduced
expression of cyclic AMP response
element-binding protein, a transcription
factor that upregulates BDNF expression.
SIRT1 deacetylates and activates the
transcriptional repressor YY1, which
then suppresses the expression of miR-
134, a brain-specific micro RNA that
selectively inhibits the production of
CREB (Figure 1). The results (Gao et al.,
2010) suggest a prominent, albeit circui-
tous role, for SIRT1 in the regulation of
synaptic plasticity and memory. Although
not addressed in the latter study, age- and
disease-related deficits in BDNF expres-
sion and cognitive function might result
from decrements in SIRT1 activity, such
as those documented in brain aging and
AD (Julien et al., 2009). Regulation of
BDNF expression by SIRT1 also suggests
potential roles for protein acetylation in
the many processes in which BDNF is
involved, including neurogenesis, brain
injury responses and depression.
Why is it that protein acetylation in
general, and SIRT1 in particular, seems
to be so intimately involved in much of
what goes wrong in neurodegenerative
dementias? The negative impact of lysine
acetylation on protein ubiquitination and
degradation is one explanation of how
a SIRT1 deficit and consequent hyper-
acetylation may cause the accumulation
of tau (directly) and Ab (indirectly via
suppression of a-secretase expression).
But the roles of SIRT1 in more funda-
mental aspects of aging provide addi-
tional clues; SIRT1 is an ortholog of
SIR2, a deacetylase known to promote
longevity in invertebrates. In rodents,
SIRT1mediates, at least in part, extension
of lifespan and suppression of cancers
and diabetes by dietary energy restriction.
These effects of SIRT1 on aging involve
deacetylation of several protein sub-902 Neuron 67, September 23, 2010 ª2010 Estrates, including PGC-1a and the tumor
suppressor p53. Interestingly, dietary
energy restriction has been shown to
suppress Ab and tau accumulation in
mousemodels of AD, whichmay bemedi-
ated, in part, by upregulation of a-secre-
tase (Qin et al., 2006; Halagappa et al.,
2007). Other studies have shown that
energy restriction upregulates the expres-
sion of BDNF and PGC-1a, key regulators
of cellular energy metabolism, oxidative
stress, and inflammation in the brain
(Martin et al., 2008; Arumugam et al.,
2010). Thus, by deacetylating and acti-
vating proteins that regulate major cellular
stress resistance pathways, and by
promoting removal of potentially toxic
proteins such as p-tau and Ab, SIRT1
may protect neurons against the dark
forces of aging and disease.
The recent flurry of information impli-
cating different acetoproteins in the path-
ogenesis of dementias suggests the
possibility of targeting specific lysine
acetyltransferases and deacetylases in
the development of novel therapeutic
interventions. In this regard, much
remains to be understood of how protein
acetylation regulation goes awry and
how it contributes to key events in neuro-
degenerative disorders. Which specific
enzymes acetylate tau, APP-processing
enzymes, YY1, and other proteins
involved in the pathogenesis of AD?
Does an increase in the level of such ace-
tyltransferases increase in tauopathies?
What of lysine deacetylases other than
SIRT1—do they modify the acetylation
state of proteins involved in neuronal plas-
ticity and survival? Does the acetylation of
specific lysines affect the phosphorylation
state of nearby serine, threonine, or tyro-
sine residues in phosphoproteins involved
in learning and memory? Inhibitors and
activators of lysine deacetylases, and
inhibitors of acetyltransferases should be
vigorously pursued in translational
research efforts to combat AD and FTD,
diseases for which effective treatments
are urgently needed.lsevier Inc.REFERENCES
Arumugam, T.V., Phillips, T.M., Cheng, A., Morrell,
C.H., Mattson,M.P., andWan, R. (2010). Ann. Neu-
rol. 67, 41–52.
Donmez, G.,Wang, D., Cohen, D.E., andGuarente,
L. (2010). Cell 142, 320–332.
Gao, J., Wang, W., Mao, Y., Graff, J., Guan, J.,
Pan, L., Mak, G., Kim, D., Su, S.C., and Tsai, L.H.
(2010). Nature 466, 1105–1109.
Goedert, M., Klug, A., and Crowther, R.A. (2006). J.
Alzheimers Dis. 9, S195–S207.
Halagappa, V.K., Guo, Z., Pearson, M., Matsuoka,
Y., Cutler, R.G., Laferla, F.M., and Mattson, M.P.
(2007). Neurobiol. Dis. 26, 212–220.
Julien, C., Tremblay, C., Emond, V., Lebbadi, M.,
Salem, N., Jr., Bennett, D.A., and Calon, F.
(2009). J. Neuropathol. Exp. Neurol. 68, 48–58.
Martin, B., Pearson, M., Brenneman, R., Golden,
E., Keselman, A., Iyun, T., Carlson, O.D., Egan,
J.M., Becker, K.G., Wood, W., III., et al. (2008).
PLoS One 3, e2398.
Mattson, M.P., Maudsley, S., andMartin, B. (2004).
Trends Neurosci. 27, 589–594.
Micha´n, S., Li, Y., Chou, M.M., Parrella, E., Ge, H.,
Long, J.M., Allard, J.S., Lewis, K., Miller, M., Xu,
W., et al. (2010). J. Neurosci. 30, 9695–9707.
Min, S.W., Cho, S.H., Zhou, Y., Schroeder, S.,
Haroutunian, V., Seeley, W.W., Huang, E.J.,
Shen, Y., Masliah, E., Mukherjee, C., et al. (2010).
Neuron 67, this issue, 953–966.
Petrucelli, L., Dickson, D., Kehoe, K., Taylor, J.,
Snyder, H., Grover, A., De Lucia, M., McGowan,
E., Lewis, J., Prihar, G., et al. (2004). Hum. Mol.
Genet. 13, 703–714.
Polydoro, M., Acker, C.M., Duff, K., Castillo, P.E.,
and Davies, P. (2009). J. Neurosci. 29, 10741–
17109.
Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen,
L., Zhao, W., Thiyagarajan, M., MacGrogan, D.,
Rodgers, J.T., et al. (2006). J. Biol. Chem. 281,
21745–21754.
Stomrud, E., Hansson, O., Zetterberg, H., Blen-
now, K., Minthon, L., and Londos, E. (2010). Arch.
Neurol. 67, 217–223.
Wayman, G.A., Lee, Y.S., Tokumitsu, H., Silva,
A.J., and Soderling, T.R. (2008). Neuron 59,
914–931.
Yang, X.J., and Seto, E. (2008). Mol. Cell 31,
449–461.
